Repaglinide 0.5 mg (Generic)

What is Repaglinide 0.5 mg?

Repaglinide belongs to the meglitinide class of antidiabetic agents, which function by stimulating insulin release from pancreatic beta cells in a glucose‑dependent manner. Unlike some other oral hypoglycemics, repaglinide’s mechanism is rapid‑acting and short‑lived, making it particularly suitable for controlling post‑prandial (after‑meal) glucose spikes. The 0.5 mg strength is the most commonly prescribed dosage for initiation, allowing clinicians to titrate up or down based on therapeutic response and tolerability. While the active ingredient is chemically synthesized, the formulation adheres to strict pharmaceutical standards set by the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO). For more detailed scientific information, refer to the National Center for Biotechnology Information.

Uses and Benefits

The primary use of repaglinide 0.5 mg is to lower elevated blood glucose levels in adults with type 2 diabetes who have not achieved adequate control with lifestyle modification alone. Clinical studies demonstrate that repaglinide effectively reduces post‑prandial glucose excursions, thereby decreasing the risk of hyperglycemic complications such as diabetic ketoacidosis. Patients often experience improved glycemic variability and a lower incidence of hypoglycemia compared with some sulfonylureas, because repaglinide’s action ceases quickly when glucose levels fall. Additionally, its flexible dosing schedule — typically taken before each main meal — allows for individualized treatment plans that can be integrated into diverse daily routines. The medication is also compatible with other glucose‑lowering agents, enabling combination therapy under medical supervision.

How It Works

Repaglinide exerts its pharmacological effect by binding to ATP‑dependent potassium channels on the surface of pancreatic beta cells. This binding triggers a cascade that leads to rapid influx of calcium ions, prompting the exocytosis of stored insulin granules. Because the drug’s activity is tightly linked to circulating glucose concentrations, insulin release is modulated in real time, preventing excessive insulin secretion during low‑glucose states. This glucose‑dependent mechanism contributes to a reduced risk of hypoglycemia and supports more physiologic insulin secretion patterns. The medication is rapidly absorbed after oral administration, with peak plasma concentrations achieved within one to two hours, and is primarily metabolized by the liver enzyme CYP2C8 and eliminated through biliary excretion. For a comprehensive overview of repaglinide’s pharmacokinetics, consult the U.S. Food and Drug Administration labeling.

Dosage Guidelines

Typical initiation of repaglinide therapy involves a 0.5 mg dose taken orally before the main meals, usually three times daily. The dosage may be titrated upward in increments of 0.5 mg based on fasting or post‑prandial glucose measurements, with a maximum recommended daily dose of 4 mg divided across meals. Patients with hepatic impairment or those taking certain CYP2C8 inhibitors may require dose reduction to avoid accumulation. It is essential to monitor blood glucose regularly and adjust the dose only under the guidance of a qualified healthcare professional. Missed doses should be skipped rather than doubled, and the medication should be stored at room temperature, protected from moisture and heat. For detailed dosing algorithms, refer to the MedlinePlus resource.

Side Effects

Like all pharmaceutical products, repaglinide 0.5 mg can be associated with adverse effects. The most commonly reported side effects include hypoglycemia, especially when combined with other insulin secretagogues, gastrointestinal discomfort such as nausea or diarrhea, and weight gain. Less frequent but clinically significant events may involve hepatic enzyme elevations, allergic skin reactions, and rare instances of hepatic dysfunction. Patients should be instructed to seek immediate medical attention if they experience severe hypoglycemia, persistent abdominal pain, or signs of an allergic reaction such as rash or swelling. Regular laboratory monitoring of liver function tests is recommended during long‑term therapy. For an extensive list of reported adverse events, consult the Drugs.com monograph.

Warnings and Precautions

Repaglinide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and it should not be used in individuals with type 1 diabetes or diabetic ketoacidosis. Caution is advised in patients with moderate to severe hepatic impairment, as well as in those with adrenal or pituitary insufficiency, because these conditions may increase the risk of hypoglycemia. Concomitant use of certain medications, including gemfibrozil and some antifungal agents, may alter repaglinide metabolism and necessitate dose adjustments. Pregnant or breastfeeding women should only use repaglinide if the potential benefits outweigh the risks, and such use must be supervised by a healthcare provider. Patients should be educated about the signs of low blood sugar and instructed to carry a source of glucose at all times. For official prescribing information, refer to the FDA’s labeling database.

Frequently Asked Questions

1. Can I take repaglinide if I miss a dose before a meal? If you forget to take a dose before a scheduled meal, simply skip that dose and resume your regular dosing schedule at the next meal; do not double the dose.
2. Is repaglinide safe to use with insulin therapy? Repaglinide can be combined with insulin, but close glucose monitoring is essential because the combination increases the risk of hypoglycemia; dosage adjustments are typically required.
3. How quickly does repaglinide lower blood sugar? Repaglinide begins to lower post‑prandial glucose within one to two hours after ingestion, with maximal effect observed around four hours.
4. Do I need to adjust my diet while taking repaglinide? Yes, repaglinide works best as part of a comprehensive treatment plan that includes a balanced diet, regular physical activity, and routine glucose monitoring.
5. Can repaglinide cause weight gain? Weight gain has been reported in some patients, so maintaining a healthy lifestyle and monitoring body weight are important components of treatment.

Related Products

• Okamet 500 Mg (Metformin)
• Novofine 31G Needle (Device)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)
• Glycomet-GP 2 Forte (Metformin/Glimepiride)
• Glycomet-GP 1 Forte (Metformin/Glimepiride)
• Glimepiride 4 mg (Generic)